Literature DB >> 14557696

Dobutamine stress echocardiography in hypertrophic cardiomyopathy.

Maria Angela Losi1, Sandro Betocchi, Mariano Aversa, Raffaella Lombardi, Marianna Miranda, Alessandra Cacace, Quirino Ciampi, Carlo Gabriele Tocchetti, Adriana Guida, Massimo Chiariello.   

Abstract

AIMS: Myocardial ischemia in the absence of coronary artery disease is common in patients with hypertrophic cardiomyopathy (HCM). Dobutamine stress echocardiography (DSE) induces left ventricular (LV) new wall motion abnormalities (NWMA) in some patients with HCM. We evaluated the effects of dobutamine on LV performance and hemodynamics in HCM. METHODS AND
RESULTS: Eighteen patients with non-obstructive HCM underwent DSE. Dobutamine was administered at dosages of 5, 10, 20, 30 and 40 microg/kg/min with increments at intervals of 3 min. Seven patients developed NWMA, whereas the other 11 did not. During DSE, heart rate increased significantly more in NWMA patients,whereas LV outflow tract gradient (OTG) increased significantly and similarly in both groups. At peak dobutamine dose, NWMA patients had a significant increase in LV end-systolic diameter and volume and a significant decrease in LV fractional shortening and ejection fraction. Posterior wall thickening increased significantly, whereas septal thickening did not increase throughout DSE in both groups.
CONCLUSIONS: In a subgroup of patients with HCM, DSE induces NWMA, associated with a greater increase in heart rate, irrespective of LVOTG. NWMA induce a depression of global LV systolic performance. The septum shows no contractile reserve, regardless of NWMA. These phenomena may be the result of induction of ischemia and/or impaired LV systolic function due to fast heart rate. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557696     DOI: 10.1159/000073045

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  4 in total

Review 1.  Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Aurelio Sgalambro; Massimo Baldi; Barbara Sotgia; Davide Antoniucci; Paolo G Camici; Roberto Sciagrà; Iacopo Olivotto
Journal:  J Cardiovasc Transl Res       Date:  2009-11-03       Impact factor: 4.132

2.  Left ventricular outflow tract obstruction caused by massive mitral annular calcification in a patient with hypertensive heart disease.

Authors:  Naofumi Yoshida; Tatsuya Miyoshi; Taira Ninomaru; Yuichi Nagamatsu; Naoki Tamada; Noritoshi Hiranuma; Yoshihiro Sasaki; Aki Kitamura; Gaku Kanda; Noriyasu Kobayashi; Keitaro Nakagiri; Takashi Fujii
Journal:  J Cardiol Cases       Date:  2015-06-12

Review 3.  Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment.

Authors:  Maria-Angela Losi; Stefano Nistri; Maurizio Galderisi; Sandro Betocchi; Franco Cecchi; Iacopo Olivotto; Eustachio Agricola; Piercarlo Ballo; Simona Buralli; Antonello D'Andrea; Arcangelo D'Errico; Donato Mele; Susanna Sciomer; Sergio Mondillo
Journal:  Cardiovasc Ultrasound       Date:  2010-03-17       Impact factor: 2.062

4.  Cerebral vasospasm and concurrent left ventricular outflow tract obstruction: requirement for modification of hyperdynamic therapy regimen.

Authors:  Gabriel Zada; Sergei Terterov; Jonathan Russin; Leonardo Clavijo; Steven Giannotta
Journal:  Neurocrit Care       Date:  2010-04       Impact factor: 3.210

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.